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MR Imaging and Cardiac Amyloidosis
Where to Go From Here?*
Joseph B. Selvanayagam, MBBS, DPHIL,†‡ Darryl P. Leong, MBBS‡
Adelaide, AustraliaCardiac amyloidosis describes clinically significant
involvement of the heart by amyloid deposition,
which may or may not be associated with involve-
ment of other organs. Acquired systemic amyloid-
osis occurs in more than 10 per million person-years
in the U.S. population, and cardiac involvement
usually portends a poor prognosis, with or without
treatment (1). As no single noninvasive test or
See page 155
abnormality is pathognomonic of cardiac amyloid,
diagnosis of cardiac amyloid has usually relied on:
1) echocardiographic assessment, especially mea-
surement of LV wall thickness, subjective assess-
ment of myocardial appearance, and evaluation of
diastolic function/restrictive physiology; and 2) his-
topathological findings of amyloid deposition on
endomyocardial biopsy. However, both of these
means of diagnosis suffer from significant limita-
tions. Echocardiographic indicators of amyloidosis
are neither sensitive nor specific, and endomyocar-
dial biopsy is invasive, as well as being subject to
potential sampling error. Cardiac magnetic reso-
nance (CMR) has a number of appealing properties
in the evaluation of suspected amyloid heart disease.
Its high spatial resolution and signal-to-noise ratio
permit reproducible measurement of cardiac cham-
ber volumes and mass, as well as LV and atrial
septal wall thickness. It can characterize pericardial
and pleural fluid. Finally, the ‘late gadolinium
enhancement’ technique (LGE-CMR) has an es-
tablished role in ‘phenotyping’ various forms of
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the †Flinders University and the ‡Flinders Medical Centre,
Bedford Park, SA, Australia.cardiomyopathy (2). In this issue of iJACC, Syed
et al. (3) report their findings from a cross-
sectional study of 120 patients referred to a
tertiary center with confirmed amyloidosis. CMR
was performed at physician discretion. Endomyo-
cardial biopsy was obtained in a more severely
affected subset of patients, and interstitial amy-
loid content semiquantitatively measured. Cases
without cardiac histopathology were dichoto-
mized into those with and without evidence of
cardiac amyloid on the basis of mean LV wall
thickness 12 mm from end-diastolic septal and
inferolateral walls by echocardiography. LGE-
CMR was performed 7 to 12 min after 0.2
mmol/kg gadodiamide. The selection of optimal
inversion time (TI), especially difficult in this
patient group, was performed using a multi-TI
cine fast echo sequence.
Among patients with histologically confirmed
cardiac amyloid, increased echocardiographic wall
thickness was observed in 91% and LGE in 97% of
cases. The pattern of LGE was global (transmural
or subendocardial) in 83%, patchy focal in 6%,
while in 8% there was suboptimal nulling. Subop-
timal nulling was defined where adequately nulled
“black” myocardium could not be obtained despite
the use of multiple TIs; these differed from
diffuse LGE in that they did not have hyper-
enhanced myocardium. The presence of global
LGE was associated with more severe interstitial
cardiac amyloid deposition. Among individuals
without cardiac histology but with increased
echocardiographic wall thickness, there was
global LGE in 53%, patchy focal LGE in 12%,
suboptimal nulling in 20%, and no LGE in 14%.
Of the patients without cardiac histology and
with normal echocardiographic wall thickness,
there was global LGE in 8%, patchy focal LGE
in 22%, suboptimal nulling in 17%, and no LGE
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166n 53%. There was a biologically plausible asso-
iation between degree of LGE and markers of
isease severity, including New York Heart As-
ociation functional class, CMR measures of
ardiac mass and ejection fraction, electrocardio-
raphic parameters, and cardiac biomarkers.
The major strength of the present study by Syed
t al. (3) lies in the 35 patients with histological
onfirmation of cardiac amyloid. It corroborates
with greater patient numbers) the findings of
erugini et al. (4), who reported similar findings in
1 patients with cardiac amyloid. Although the
revalence of LGE reported by Syed et al. (3) is
imilar to that observed by Maceira et al. (5), the
attern of LGE differed in that it was global
ubendocardial in all cases in the series of Maceira
t al. (5), whereas it was more commonly transmu-
al in those with histopathologically confirmed
ardiac amyloid in the present study. Vogelsberg
t al. (6) also reported a global subendocardial
attern of LGE in cardiac amyloid cases. The
uthors, correctly, attribute such discrepant findings
o variation in the dose of contrast across these
tudies and timing of imaging after its administra-
ion. Allied to the timing of imaging after contrast
dministration is the selection of TI at which LGE
s measured. The diffuse nature of cardiac amyloid,
nd the alteration in myocardial gadolinium kinet-
cs in this condition make TI selection crucially
mportant in its detection by CMR. A limitation in
he widespread application of LGE-CMR in iden-
ifying cardiac amyloid is the reproducibility with
hich this can be performed, and a more standard-
zed technique is desirable.
Three significant potential weaknesses of this
tudy merit discussion. First, the key question of
hether LGE-CMR can identify cardiac amyloid
arlier in the disease process than detection of
orphological changes (by standard echocardiogra-
hy) remains incompletely answered by this study.
t is this group of patients that should draw partic-
lar attention, however, because they may be most
ikely to benefit from disease-modifying, and po-
entially life-prolonging, therapy. Second, CMR
as performed at a tertiary referral center at attend-
ng physician discretion, which would have intro-
uced a significant selection bias. This makes it
ifficult to define the sensitivity and specificity of
he LGE-CMR technique in detecting early (i.e.,
ith normal LV wall thickness) cardiac amyloidosis
rom the authors’ data. Third, in the patients
ithout a cardiac biopsy (who form the majority ofhe study cohort), the echocardiographic criteria flsed to diagnose cardiac amyloid are only moder-
tely specific. A mean LV wall thickness 12 mm
s not uncommon, and can often be found in
ystemic hypertension, the prevalence of which is
ot stated in this cohort. While previous myocardial
nfarction was an exclusion criterion, systematic
oronary angiography was not undertaken to ex-
lude ischemic heart disease as a cause for LGE. It
s conceivable that some of the LGE findings in this
ubgroup might represent occult coronary artery
isease. The absence of endomyocardial biopsy data
rom patients with normal wall thickness renders
his report’s LGE data speculative, rather than
efinitive, despite the relationship between LGE
resence and surrogate markers of cardiac involve-
ent in this subgroup.
This and other recent studies also raise the
uestion of whether a positive LGE-CMR result
an obviate the need for endomyocardial biopsy for
he diagnosis of cardiac involvement in patients
ith known amyloidosis. CMR would appear a
easonable alternative to endomyocardial biopsy
n patients with tissue diagnosis from an alternate
ite and thought to be at high risk for invasive
nvestigation, particularly where classic CMR
ndings of cardiac amyloid are identified. The
dvantage of an imaging modality for the recog-
ition of cardiac amyloid is its ability to interro-
ate the entire heart, whereas biopsy can suffer
rom a sampling error (7).
The prognostic significance of the finding of
GE or suboptimal nulling cannot be determined
rom this cross-sectional study. Recent evidence
rom Maceira et al. (8), in a cohort of 29 patients,
uggests that T1 mapping may have greater ability
o predict outcome than LGE per se, possibly as it
ore accurately reflects the myocardial interstitial
myloid load. However, the additive value of this
echnique to existing prognostic indicators requires
onfirmation in larger series. Lastly, work from
apezzi et al. (9) highlights the difference in out-
ome between different types of cardiac amyloid-
sis. Whether CMR has an independent discrimi-
atory role across these subtypes is unknown. This
s a fertile area of continuing research, and the study
y Syed et al. (3) is an important step along the
ourney in identifying early imaging markers of
ardiac amyloidosis.
eprint requests and correspondence: Dr. Joseph B. Sel-
anayagam, Department of Cardiovascular Medicine, Flin-
ers University, Flinders Medical Centre, Bedford Park,
A, 5042 Australia. E-mail: joseph.selvanayagam@
inders.edu.au.
R1
2
3
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 2 , 2 0 1 0
F E B R U A R Y 2 0 1 0 : 1 6 5 – 7
Selvanayagam and Leong
Editorial Comment
1678
9
K
cE F E R E N C E S
. Selvanayagam JB, Hawkins PN, Paul
B, Myerson SG, Neubauer S. Evaluation
and management of the cardiac amyloid-
osis. J Am Coll Cardiol 2007;50:2101–10.
. Mahrholdt H, Wagner A, Judd RM,
Sechtem U, Kim RJ. Delayed enhance-
ment cardiovascular magnetic reso-
nance assessment of non-ischaemic car-
diomyopathies. Eur Heart J 2005;26:
1461–74.
. Syed IS, Glockner JF, Feng DL, et al.
Role of cardiac magnetic resonance im-
aging in the detection of cardiac amy-
loidosis. J Am Coll Cardiol Img 2010;
3:155–64.4. Perugini E, Rapezzi C, Piva T, et al.
Non-invasive evaluation of the myocar-
dial substrate of cardiac amyloidosis by
gadolinium cardiac magnetic reso-
nance. Heart 2006;92:343–9.
5. Maceira AM, Joshi J, Prasad SK, et al.
Cardiovascular magnetic resonance in
cardiac amyloidosis. Circulation 2005;
111:186–93.
6. Vogelsberg H, Mahrholdt H, Deluigi
CC, et al. Cardiovascular magnetic res-
onance in clinically suspected cardiac
amyloidosis: noninvasive imaging com-
pared to endomyocardial biopsy. J Am
Coll Cardiol 2008;51:1022–30.
7. Pellikka PA, Holmes DR Jr., Edwards
WD, Nishimura RA, Tajik AJ, Kyle
RA. Endomyocardial biopsy in 30 pa- ltients with primary amyloidosis and
suspected cardiac involvement. Arch
Intern Med 1988;148:662–6.
. Maceira AM, Prasad SK, Hawkins PN,
Roughton M, Pennell DJ. Cardiovas-
cular magnetic resonance and prognosis
in cardiac amyloidosis. J Cardiovasc
Magn Reson 2008;10:54.
. Rapezzi C, Merlini G, Quarta CC, et
al. Systemic cardiac amyloidoses. Disease
profiles and clinical courses of the 3 main
types. Circulation 2009;120:1203–12.
ey Words: amyloidosis y
ardiac magnetic resonance y
ate gadolinium enhancement.
